

Page 001 of 136 to/à Page 005 of 136

Withheld pursuant to/removed as

s.13 ; s.17

Page 006 of 136

Withheld pursuant to/removed as

s.13 ; s.14 ; s.16 ; s.17

Page 007 of 136 to/à Page 008 of 136

Withheld pursuant to/removed as

s.13 ; s.14 ; s.17

Page 009 of 136

Withheld pursuant to/removed as

s.13 ; s.17

Page 010 of 136

Withheld pursuant to/removed as

s.13 ; s.16 ; s.17

Page 011 of 136

Withheld pursuant to/removed as

s.13 ; s.17

RE: Placeholder - s.13; s.17

From: Tupper, Kenneth HLTH:EX^{s.15}
:

To: Bouma, Susan HLTH:EX

Cc: Eaton, Eva HLTH:EX

Sent: November 18, 2020 12:00:21 PM PST

Hi Sue – unfortunately, I’m chairing another meeting at this time and can’t make this . . . any way it can be rescheduled?

-----Original Appointment-----

From: Scott, Kimberly B HLTH:EX <Kimberly.B.Scott@gov.bc.ca> **On Behalf Of** Bouma, Susan HLTH:EX

Sent: November 18, 2020 11:37 AM

To: Tupper, Kenneth HLTH:EX; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; SMacDonald2@providencehealth.bc.ca; Eugenia Oviedo-Joekes; Alain Boisvert; albailey@pharmascience.com

Subject: Placeholder -s.13; s.17

When: November 27, 2020 2:00 PM-3:00 PM (UTC-08:00) Pacific Time (US & Canada).

Where:

More information to come.

RE: Placeholder - s.13; s.17

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
To: Tupper, Kenneth HLTH:EX <Kenneth.Tupper@gov.bc.ca>
Cc: Eaton, Eva HLTH:EX <Eva.Eaton@gov.bc.ca>
Sent: November 18, 2020 12:40:40 PM PST

Will do

From: Tupper, Kenneth HLTH:EX <Kenneth.Tupper@gov.bc.ca>

Sent: November 18, 2020 12:00 PM

To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Cc: Eaton, Eva HLTH:EX <Eva.Eaton@gov.bc.ca>

Subject: RE: Placeholder -s.13; s.17

Hi Sue – unfortunately, I’m chairing another meeting at this time and can’t make this . . . any way it can be rescheduled?

-----Original Appointment-----

From: Scott, Kimberly B HLTH:EX <Kimberly.B.Scott@gov.bc.ca> **On Behalf Of** Bouma, Susan HLTH:EX

Sent: November 18, 2020 11:37 AM

To: Tupper, Kenneth HLTH:EX; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; SMacDonald2@providencehealth.bc.ca; Eugenia Oviedo-Joekes; Alain Boisvert; albailey@pharmascience.com

Subject: Placeholder - s.13; s.17

When: November 27, 2020 2:00 PM-3:00 PM (UTC-08:00) Pacific Time (US & Canada).

Where:

More information to come.

From: Alain Boisvert <aboisvert@pharmascience.com>
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>, Tupper, Kenneth HLTH:EX <Kenneth.Tupper@gov.bc.ca>, Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>, Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>, SMacDonald2@providencehealth.bc.ca, Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>, Andrea Lee Bailey <albailey@pharmascience.com>
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Sent: December 2, 2020 1:09:29 PM PST
Attachments: Dec 4 2020 - Meeting Agenda.pdf, Questions Dec 4 mtg.pdf

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Dear Susan,

In preparation for our meeting of Dec 4, here is a proposed agenda and the questions we would like to raise. It is a broad set of questions but many can be answered rapidly, so hopefully we will be able to cover them all during the meeting.

Once again thank you for making the time, We look forward to meeting you on Friday.

Alain

-----Original Appointment-----

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Sent: Wednesday, November 18, 2020 2:37 PM

To: Bouma, Susan HLTH:EX; Tupper, Kenneth HLTH:EX; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; SMacDonald2@providencehealth.bc.ca; Eugenia Oviedo-Joekes; Alain Boisvert; Andrea Lee Bailey

Cc: s.22 Bruce Valliant

Subject: s.13; s.17 Pharmascience

When: Friday, December 4, 2020 1:00 PM-2:00 PM (UTC-08:00) Pacific Time (US & Canada).

Where: Microsoft Teams Meeting

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

[Learn More](#) | [Meeting options](#)

For instructions on how to download Microsoft Teams click [here](#).

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

Page 015 of 136 to/à Page 019 of 136

Withheld pursuant to/removed as

s.13 ; s.17

From: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>
 To: Alain Boisvert <aboisvert@pharmascience.com>, Bouma, Susan HLTH:EX
 <Susan.Bouma@gov.bc.ca>, kenneth.tupper@gov.bc.ca [EXT]
 <kenneth.tupper@gov.bc.ca>, Koleba, Tamar [VCH]
 <Tamar.Koleba@vch.ca>, Sutton, Mason HLTH:EX
 <Mason.Sutton@gov.bc.ca>, Pollock, Lynn L HLTH:EX
 <Lynn.Pollock@gov.bc.ca>, Eugenia Oviedo-Joekes
 <eugenia@cheos.ubc.ca>, Andrea Lee Bailey
 <albailey@pharmascience.com>, Tupper, Kenneth HLTH:EX
 Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
 Sent: December 4, 2020 2:44:58 PM PST
 Attachments: s.13; s.17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi all,
 Thanks for the discussion today. Glad to hear progress is being made toward a s.13; s.17
 I have attached some brief answers to the questions. Happy to expand on these s.13
 Cheers,
 Scott
 D. Scott MacDonald M.D.
 Physician Lead
 Providence Crosstown Clinic
 84 West Hastings Street
 Vancouver, BC V6B 1G6
Phone: 604-689-8803
Fax: 604-689-3996
Smacdonald2@providencehealth.bc.ca
<https://twitter.com/DrScott>

From: Alain Boisvert [mailto:aboisvert@pharmascience.com]
Sent: Wednesday, December 02, 2020 1:09 PM
To: Bouma, Susan HLTH:EX; kenneth.tupper@gov.bc.ca [EXT]; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; MacDonald, Scott [PH]; Eugenia Oviedo-Joekes; Andrea Lee Bailey
Cc: s.22 Bruce Valliant
Subject: RE: s.13; s.17 Pharmascience
EXTERNAL SENDER. If you suspect this message is malicious, please forward to spam@phsa.ca and **do not** open attachments or click on links.

Dear Susan,
 In preparation for our meeting of Dec 4, here is a proposed agenda and the questions we would like to raise. It is an broad set of questions but many can be answered rapidly, so hopefully we will be able to cover them all during the meeting.
 Once again thank you for making the time, We look forward to meeting you on Friday.
 Alain
 -----Original Appointment-----
From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: Wednesday, November 18, 2020 2:37 PM
To: Bouma, Susan HLTH:EX; Tupper, Kenneth HLTH:EX; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; SMacDonald2@providencehealth.bc.ca; Eugenia Oviedo-Joekes; Alain Boisvert; Andrea Lee Bailey
Cc: s.22 Bruce Valliant
Subject: s.13; s.17 Pharmascience
When: Friday, December 4, 2020 1:00 PM-2:00 PM (UTC-08:00) Pacific Time (US & Canada).
Where: Microsoft Teams Meeting

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

[Learn More](#) | [Meeting options](#)

For instructions on how to download Microsoft Teams click [here](#).

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

Page 022 of 136 to/à Page 028 of 136

Withheld pursuant to/removed as

s.13 ; s.17

From: Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>
To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>, Alain Boisvert <aboisvert@pharmascience.com>, Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>, kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>, Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>, Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>, Andrea Lee Bailey <albailey@pharmascience.com>, Tupper, Kenneth HLTH:EX
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Sent: December 6, 2020 12:09:57 PM PST
Attachments: s.13; s.17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi all,

Please find attached some pharmacy and clinic documents from Crosstown Clinic. I will send the Fraser Health Clinic s.13; s.17 and clinic procedures later this week (twice daily administration at the FH clinic).

Thanks,

Tamar

Cell 604-839-6804

Administrative Assistant: Jasper Clinaz

jasper.clinaz1@vch.ca

From: MacDonald, Scott [PH]

Sent: Friday, December 04, 2020 2:45 PM

To: 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>

Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>

Subject: RE: s.13; s.17 Pharmascience

Hi all,

Thanks for the discussion today. Glad to hear progress is being made toward a s.13; s.17

I have attached some brief answers to the questions. Happy to expand on these s.13

Cheers,

Scott

D. Scott MacDonald M.D.

Physician Lead

Providence Crosstown Clinic

84 West Hastings Street

Vancouver, BC V6B 1G6

Phone: 604-689-8803

Fax: 604-689-3996

Smacdonald2@providencehealth.bc.ca

<https://twitter.com/DrScott>

From: Alain Boisvert [<mailto:aboisvert@pharmascience.com>]

Sent: Wednesday, December 02, 2020 1:09 PM

To: Bouma, Susan HLTH:EX; kenneth.tupper@gov.bc.ca [EXT]; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; MacDonald, Scott [PH]; Eugenia Oviedo-Joekes; Andrea Lee Bailey

Cc: s.22 Bruce Valliant

Subject: RE:s.13; s.17 Pharmascience

EXTERNAL SENDER. If you suspect this message is malicious, please forward to spam@phsa.ca and **do not** open attachments or click on links.

Dear Susan,

In preparation for our meeting on Dec 4, here is a proposed agenda and the questions we would like to raise. It is a broad set of questions but many can be answered rapidly, so hopefully we will be able to cover them all during the meeting.

Once again thank you for making the time, We look forward to meeting you on Friday.

Alain

-----Original Appointment-----

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Sent: Wednesday, November 18, 2020 2:37 PM

To: Bouma, Susan HLTH:EX; Tupper, Kenneth HLTH:EX; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; SMacDonald2@providencehealth.bc.ca; Eugenia Oviedo-Joekes; Alain Boisvert; Andrea Lee Bailey

Cc: s.22 Bruce Valliant

Subject: s.13; s.17 Pharmascience

When: Friday, December 4, 2020 1:00 PM-2:00 PM (UTC-08:00) Pacific Time (US & Canada).

Where: Microsoft Teams Meeting

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

[Learn More](#) | [Meeting options](#)

For instructions on how to download Microsoft Teams click [here](#).

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

Page 031 of 136 to/à Page 078 of 136

Withheld pursuant to/removed as

s.13

From: Andrea Lee Bailey <albailey@pharmascience.com>
To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>, Alain Boisvert <aboisvert@pharmascience.com>, Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>, kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>, Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>, Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>, Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>, Tupper, Kenneth HLTH:EX
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Sent: December 7, 2020 9:07:40 AM PST

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Dear Scott,
Many thanks for the information.
Kind regards,
Andrea
Andrea Bailey, PhD.
Senior Regulatory Affairs Specialist – Clinical

Spécialiste principal des affaires réglementaires- Clinique

Pharmascience Inc. | 6111 Royalmount Ave., Montreal (Quebec) H4P 2T4
☎ 1(800) 363-8805 / (438)-315-3494
✉ albailey@pharmascience.com | www.pharmascience.com

From: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>
Sent: Friday, December 4, 2020 5:45 PM
To: Alain Boisvert <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Subject: RE: s.13; s.17 Pharmascience

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Hi all,
Thanks for the discussion today. Glad to hear progress is being made toward a s.13; s.17
I have attached some brief answers to the questions. Happy to expand on these s.13
Cheers,
Scott
D. Scott MacDonald M.D.
Physician Lead
Providence Crosstown Clinic
84 West Hastings Street
Vancouver, BC V6B 1G6
Phone: 604-689-8803
Fax: 604-689-3996
Smacdonald2@providencehealth.bc.ca
<https://twitter.com/DrScott>

From: Alain Boisvert [<mailto:aboisvert@pharmascience.com>]
Sent: Wednesday, December 02, 2020 1:09 PM

To: Bouma, Susan HLTH:EX; kenneth.tupper@gov.bc.ca [EXT]; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; MacDonald, Scott [PH]; Eugenia Oviedo-Joekes; Andrea Lee Bailey
Cc: s.22 Bruce Valliant
Subject: RE:s.13; s.17 Pharmascience
EXTERNAL SENDER. If you suspect this message is malicious, please forward to spam@phsa.ca and **do not** open attachments or click on links.

Dear Susan,

In preparation for our meeting on Dec 4, here is a proposed agenda and the questions we would like to raise. It is an broad set of questions but many can be answered rapidly, so hopefully we will be able to cover them all during the meeting.

Once again thank you for making the time, We look forward to meeting you on Friday.

Alain

-----Original Appointment-----

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Sent: Wednesday, November 18, 2020 2:37 PM

To: Bouma, Susan HLTH:EX; Tupper, Kenneth HLTH:EX; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; SMacDonald2@providencehealth.bc.ca; Eugenia Oviedo-Joekes; Alain Boisvert; Andrea Lee Bailey

Cc: s.22 Bruce Valliant

Subject: s.13; s.17 Pharmascience

When: Friday, December 4, 2020 1:00 PM-2:00 PM (UTC-08:00) Pacific Time (US & Canada).

Where: Microsoft Teams Meeting

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

[Learn More](#) | [Meeting options](#)

For instructions on how to download Microsoft Teams click [here](#).

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

From: Andrea Lee Bailey <albailey@pharmascience.com>
To: Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>, MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>, Alain Boisvert <aboisvert@pharmascience.com>, Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>, kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>, Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>, Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>, Tupper, Kenneth HLTH:EX
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Sent: December 7, 2020 9:07:44 AM PST

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Tamar,
Thank you for sharing this information. This is very helpful.
Kind regards,
Andrea
Andrea Bailey, PhD.
Senior Regulatory Affairs Specialist – Clinical

Spécialiste principal des affaires réglementaires- Clinique

Pharmascience Inc. | 6111 Royalmount Ave., Montreal (Quebec) H4P 2T4
☎ 1(800) 363-8805 / (438)-315-3494
✉ albailey@pharmascience.com | www.pharmascience.com

From: Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>
Sent: Sunday, December 6, 2020 3:10 PM
To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>; Alain Boisvert <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Subject: RE: s.13; s.17 Pharmascience

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Hi all,
Please find attached some pharmacy and clinic documents from Crosstown Clinic. I will send the Fraser Health Clinic
s.13; s.17 and clinic procedures later this week (twice daily administration at the FH clinic).

Thanks,

Tamar

Cell 604-839-6804
Administrative Assistant: Jasper Clinaz
jasper.clinaz1@vch.ca

From: MacDonald, Scott [PH]
Sent: Friday, December 04, 2020 2:45 PM
To: 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>

Cc:s.22 Bruce Valliant <bvallian@pharmascience.com>
Subject: RE:s.13; s.17 Pharmascience

Hi all,

Thanks for the discussion today. Glad to hear progress is being made toward a s.13; s.17

I have attached some brief answers to the questions. Happy to expand on these s.13

Cheers,

Scott

D. Scott MacDonald M.D.

Physician Lead

Providence Crosstown Clinic

84 West Hastings Street

Vancouver, BC V6B 1G6

Phone: 604-689-8803

Fax: 604-689-3996

Smacdonald2@providencehealth.bc.ca

[https://twitter.com/ DrScott](https://twitter.com/DrScott)

From: Alain Boisvert [<mailto:aboisvert@pharmascience.com>]

Sent: Wednesday, December 02, 2020 1:09 PM

To: Bouma, Susan HLTH:EX; kenneth.tupper@gov.bc.ca [EXT]; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; MacDonald, Scott [PH]; Eugenia Oviedo-Joekes; Andrea Lee Bailey

Cc:s.22 Bruce Valliant

Subject: RE: s.13; s.17 Pharmascience

EXTERNAL SENDER. If you suspect this message is malicious, please forward to spam@phsa.ca and **do not** open attachments or click on links.

Dear Susan,

In preparation for our meeting od Dec 4, here is a proposed agenda and the questions we would like to raise. It is an broad set of questions but many can be answered rapidly, so hopefully we will be able to cover them all during the meeting.

Once again thank you for making the time, We look forward to meeting you on Friday.

Alain

-----Original Appointment-----

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Sent: Wednesday, November 18, 2020 2:37 PM

To: Bouma, Susan HLTH:EX; Tupper, Kenneth HLTH:EX; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; SMacDonald2@providencehealth.bc.ca; Eugenia Oviedo-Joekes; Alain Boisvert; Andrea Lee Bailey

Cc:s.22 Bruce Valliant

Subject: s.13; s.17 Pharmascience

When: Friday, December 4, 2020 1:00 PM-2:00 PM (UTC-08:00) Pacific Time (US & Canada).

Where: Microsoft Teams Meeting

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

[Learn More](#) | [Meeting options](#)

For instructions on how to download Microsoft Teams click [here](#).

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

From: Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>
To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>, Alain Boisvert <aboisvert@pharmascience.com>, Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>, kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>, Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>, Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>, Andrea Lee Bailey <albailey@pharmascience.com>, Tupper, Kenneth HLTH:EX
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Sent: December 7, 2020 1:30:31 PM PST
Attachments: s.13; s.17 Fraser Health iOAT - Clinic Protocols and Policies 2018 (2).docx

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hello,

Please find additional documentation attached from the Fraser Health iOAT Clinic s.13; s.17

Tamar

Cell 604-839-6804

Administrative Assistant: Jasper Clinaz

jasper.clinaz1@vch.ca

From: Koleba, Tamar [VCH]

Sent: Sunday, December 06, 2020 12:10 PM

To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>; 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>

Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>

Subject: RE: s.13; s.17 Pharmascience

Hi all,

Please find attached some pharmacy and clinic documents from Crosstown Clinic. I will send the Fraser Health Clinic s.13; s.17 and clinic procedures later this week (twice daily administration at the FH clinic).

Thanks,

Tamar

Cell 604-839-6804

Administrative Assistant: Jasper Clinaz

jasper.clinaz1@vch.ca

From: MacDonald, Scott [PH]

Sent: Friday, December 04, 2020 2:45 PM

To: 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>

Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>

Subject: RE: s.13; s.17 Pharmascience

Hi all,

Thanks for the discussion today. Glad to hear progress is being made toward a domestic supply of diacetylmorphine. I have attached some brief answers to the questions. Happy to expand on these as the application proceeds.

Cheers,

Scott

D. Scott MacDonald M.D.

Physician Lead

Providence Crosstown Clinic
84 West Hastings Street
Vancouver, BC V6B 1G6
Phone: 604-689-8803
Fax: 604-689-3996
Smacdonald2@providencehealth.bc.ca
https://twitter.com/_DrScott

From: Alain Boisvert [<mailto:aboisvert@pharmascience.com>]

Sent: Wednesday, December 02, 2020 1:09 PM

To: Bouma, Susan HLTH:EX; kenneth.tupper@gov.bc.ca [EXT]; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; MacDonald, Scott [PH]; Eugenia Oviedo-Joekes; Andrea Lee Bailey

Cc: s.22 Bruce Valliant

Subject: RE: s.13; s.17 Pharmascience

EXTERNAL SENDER. If you suspect this message is malicious, please forward to spam@phsa.ca and **do not** open attachments or click on links.

Dear Susan,

In preparation for our meeting of Dec 4, here is a proposed agenda and the questions we would like to raise. It is a broad set of questions but many can be answered rapidly, so hopefully we will be able to cover them all during the meeting.

Once again thank you for making the time, We look forward to meeting you on Friday.

Alain

-----Original Appointment-----

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Sent: Wednesday, November 18, 2020 2:37 PM

To: Bouma, Susan HLTH:EX; Tupper, Kenneth HLTH:EX; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; SMacDonald2@providencehealth.bc.ca; Eugenia Oviedo-Joekes; Alain Boisvert; Andrea Lee Bailey

Cc: s.22 Bruce Valliant

Subject: s.13; s.17 Pharmascience

When: Friday, December 4, 2020 1:00 PM-2:00 PM (UTC-08:00) Pacific Time (US & Canada).

Where: Microsoft Teams Meeting

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

[Learn More](#) | [Meeting options](#)

For instructions on how to download Microsoft Teams click [here](#).

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

Page 086 of 136

Withheld pursuant to/removed as

s.13 ; s.17

iOAT Clinic

**10697 135a Street
Surrey, B.C. V3T 4E3**

**Policy and Procedure Manual 2018
Updated October 2019**

Page 088 of 136 to/à Page 100 of 136

Withheld pursuant to/removed as

Copyright

3.2 Clinic Schedule

3.2.1 Schedule overview

Session	Group	Time	Number of Patients
First Dose	1	7:00-7:30	5
	2	7:30-8:00	5
	3	8:00-8:30	5
	4	8:30-9:00	5
	5	9:00-9:30	6
	BREAK: 9:30-10:00 (1/2 hour)		
	6	10:00-10:30	6
	7	10:30-11:00	6
	8	11:00-11:30	6
	9	11:30-12:00	6
LUNCH BREAK 12:00-13:00 (1 hour)			
Second Dose	1	13:00-13:30	5
	2	13:30-14:00	5
	3	14:00-14:30	5
	4	15:00-15:30	5
	5	15:30-16:00	6
	BREAK 16:00-16:15 (15min)		
	Product Delivery 16:00-16:30		
	6	16:15-16:45	6
	7	16:45-17:15	6
	8	17:15-17:45	6
	9	17:45-18:15	6
Narcotic Count/ Finish and close 18:15-18:45			

Please note as of November 1, 2019 the clinic operates on a flexible drop in – group times will be looked at in the future if needed.

3.2.2 Detailed Schedule

Time	
0645-0700	Start of shift / am Narcotic Count
0700-0705	1st group into vestibule (5-6 clients)
0705-0710	Register clients and Pre- assessment
0710-0715	Dispense medication/ injection room observation
0715-0730	Post-assessment
0730-0735	2nd group into vestibule (5-6 clients)
0735-0740	Register and Pre-assessment
0740-0745	Dispense medication /injection room observation
0745-0800	Post-assessment
0800-0805	3rd group into vestibule (5-6 clients)
0805-0810	Register clients and Pre- assessment

0810-0815	Dispense medication/ injection room observation
0815-0830	Post-assessment
0830-0835	4 th group into vestibule (5-6 clients)
0835-0840	Register clients and Pre- assessment
0840-0845	Dispense medication/ injection room observation
0845-0900	Post-assessment
0900-0930	Staff Break (1/2 hour)
0930-0935	5 th group into vestibule (5-6 clients)
0935-0940	Register clients and Pre- assessment
0940-0945	Dispense medication/ injection room observation
0945-1000	Post-assessment
1000-1005	6 th group into vestibule (5-6 clients)
1005-1010	Register and Pre-assessment
1010-1015	Dispense medication /injection room observation
1015-1030	Post-assessment
1030-1035	7 th group into vestibule (5-6 clients)
1035-1040	Register clients and Pre- assessment
1040-1045	Dispense medication/ injection room observation
1045-1100	Post-assessment
1100-1105	8 th group into vestibule (5-6 clients)
1105-1110	Register clients and Pre- assessment
1110-1115	Dispense medication/ injection room observation
1115-1130	Post-assessment
1130-1135	9 th group into vestibule (5-6 clients)
1135-1140	Register clients and Pre- assessment
1140-1145	Dispense medication/ injection room observation
1145-1200	Post-assessment
1200-1300	LUNCH BREAK
1300-1305	1 st group into vestibule (5-6 clients)
1305-1310	Register clients and Pre- assessment
1310-1315	Dispense medication/ injection room observation
1315-1330	Post-assessment
1330-1335	2 nd group into vestibule (5-6 clients)
1335-1340	Register clients and Pre- assessment
1340-1345	Dispense medication /injection room observation
1345-1400	Post-assessment
1400-1405	3 rd group into vestibule (5-6 clients)
1405-1410	Register clients and Pre- assessment
1410-1415	Dispense medication/ injection room observation
1415-1430	Post-assessment
1430-1435	4 th group into vestibule (5-6 clients)
1435-1440	Register clients and Pre- assessment

1440-1445	Dispense medication/ injection room observation
1445-1500	Post-assessment
1500-1505	5 th group into vestibule (5-6 clients)
1505-1510	Register clients and Pre- assessment
1510-1515	Dispense medication/ injection room observation
1515-1530	Post-assessment
1530-1535	6 th group into vestibule (5-6 clients)
1535-1540	Register clients and Pre- assessment
1540-1545	Dispense medication/ injection room observation
1545-1600	Post-assessment
1600-1615	Staff Break (15 min)
	Product Delivery 1600-1630
1615-1620	7 th group into vestibule (5-6 clients)
1620-1625	Register clients and Pre- assessment
1625-1630	Dispense medication/ injection room observation
1630-1645	Post-assessment
1645-1650	8 th group into vestibule (5-6 clients)
1650-1655	Register clients and Pre- assessment
1655-1700	Dispense medication/ injection room observation
1700-1715	Post-assessment
1715-1720	9 th group into vestibule (5-6 clients)
1720-1725	Register clients and Pre- assessment
1725-1730	Dispense medication/ injection room observation
1730-1745	Post-assessment
1800-1845	Receive meds from pharmacy/ narcotic count and fax to pharmacy
1845	Closing

3.3 Hydromorphone Titration Protocol

Day 1

Dose 1: Give 10mg, wait 15 minutes. If no intoxication, give 30mg more based on clinical judgment and discussion with patient. Observe for 30 minutes after second dose.

Minimum 3 hours between injections.

Dose 2: If earlier doses were well tolerated, give 45mg. Wait 30 minutes. If no intoxication, give 30mg more based on clinical judgment and discussion with patient. Observe for 30 minutes after second dose.

Minimum 3 hours between injections.

Day 2

Dose 1: Administer 50mg, wait 30 minutes. If no intoxication, give 30mg more based on clinical judgment and discussion with patient. Observe for 30 minutes after second dose.

Minimum 3 hours between injections.

Dose 2: Administer 80mg, wait 30 minutes. If no intoxication, give 20mg more based on clinical judgment and discussion with patient. Observe for 30 minutes after second dose.

Minimum 3 hours between injections.

Day 3 and onward

Dose 1 and 2: Administer 100mg

After consulting with the physician, adjust the dosage once a week, or as needed, until the patient feels Comfortable (i.e., reduced cravings and withdrawal symptoms) and does not show any excessive intoxication or respiratory depression or until the maximum dose is reached (200mg/dose and/or 400mg/day). Dose increases are discouraged on weekends and holidays.

It should be noted that some patients may miss titration sessions due to unstable housing and other issues, and thus the initiation may require a modified protocol over multiple days.

Co-Prescription of Oral OAT

A dose of oral OAT (i.e., slow-release oral morphine) will be taken under supervision with the last dose of the day to bridge until the first dose the following morning. Caution and safety should guide co-prescription, while working to ensure patient comfort. Nurses should assess the patient each day during the titration period to ensure the co-prescribed oral OAT is appropriately dosed.

Hydromorphone Induction Dosage Chart for quick reference.

Day	Dose #	Dose Administered	Additional Dose
Day 1	Dose 1	15mg	30mg
	Dose 2	45mg	30mg
Day 2	Dose 1	50mg	30mg
	Dose 2	80mg	20mg
Day 3	Dose 1	100mg	-
	Dose 2	100mg	-

i. This protocol can be adjusted per clinical judgment. The starting dose can range between 5-15mg, as can each supplementary dose given after the observation period. If renal or hepatic impairments are present, the above dose should be halved. This protocol is based on two doses per day.

3.3.1 Diacetylmorphine Titration Protocol

- For ALL doses monitor for signs and symptoms of intoxication for 15 minutes post injection
- Nursing assess for signs and symptoms of opioid sedation and withdrawal before and after each dose using POSS
- Day 1: **diacetylmorphine** 30 mg IV/IM self-administered injection in the morning; wait 20 minutes and may provide an additional 30 mg dose if tolerated.
diacetylmorphine 60 mg IV/IM self-administered injection in the afternoon; wait 20 minutes and may provide an additional 30 mg dose if tolerated.
- Day 2: **diacetylmorphine** 90 mg IV/IM self-administered injection in the morning; wait 20 minutes and may provide an additional 30 mg dose if tolerated.
diacetylmorphine 120 mg IV/IM self-administered injection in the afternoon; wait 20 minutes and may provide an additional 30 mg dose if tolerated.
- Day 3: **diacetylmorphine** 150 mg IV/IM self-administered injection in the morning; wait 20 minutes and may provide an additional 30 mg dose if tolerated.
diacetylmorphine 180 mg IV/IM self-administered injection in the afternoon; wait 20 minutes and may provide an additional 30 mg dose if tolerated.
- Day 4 and ongoing maintenance dose:
diacetylmorphine 180 mg IV/IM self-administered injection in the morning
diacetylmorphine 180 mg IV/IM self-administered injection in the afternoon

Missed Doses on Day 1 to Day 3:

If any iOAT doses are missed in the first 3 days of titration, then:

- If one dose is missed: provide the last tolerated dose and continue with titration
- If more than one dose is missed: restart the titration schedule as Day 1

3.4 Missing Syringe Protocol

Clinical Indication:

When the nursing team is unable to locate a syringe and/or when they are not able to complete the narcotic count/inventory at the end of a shift.

Policy

Federal Narcotic Regulations stipulate that health care professionals, including RNs and RPN's, must control inventory of narcotics in the workplace.

Need to Know:

- 1) All narcotics are counted and recorded when received by the nursing team from pharmacy. Any errors are reported to pharmacy (see FHA Narcotics and Controlled Drug Policy - http://fhpulse/clinical_support_services/pharmacy/policies_pdtm_ppos_forms/FH%20Medication%20Manual/Narcotics%20and%20Controlled%20Drugs.pdf)
- 2) All syringes are identified and counted at the end of each group by the same nurse that administered the syringes (med room nurse).. Syringes are checked for emptiness, label presence and signs of tampering (ie same BD syringe brand, special marking on syringe placed randomly by staff)

PRACTICE GUIDELINE

Equipment & Supplies:

Tongs for looking through garbage and large sharps bin

Procedure:

Situation 1: Syringe missing after a group has been in the Injection Room (IR)

- The cage nurse is responsible for counting and checking all syringes at the end of IR time. This must be done prior to the group leaving the clinic.
- If a syringe cannot be found then the cage nurse notifies the assistants to hold clients in the clinic.
- The assessment nurse assists the med room nurse in the search for the syringe.
- The sharps bin, garbage and surrounding area is searched using tongs and gloves.
- The coordinator speaks to the client in a private space about the missing syringe
- If syringe found – client given a verbal warning and reminder about the importance of returning the syringe into the bin.
- If syringe not found – client is asked to search their belongings in front of 2 staff to check to see if it is on their person or in belongings
 - If found – syringe is returned and a behavior contract is signed
 - If not found – client meets with Clinic Coordinator (CC) regarding incident and then sees MD for medication support if they are going to miss sessions.

Situation 2: Syringe not found at inventory count

- Nurse doing count and a second nurse check all bins and surrounding area including HDM safe and DAM fridge

- Coordinator checks fridge and vault for loose syringe
- All staff on shift are asked to check their belongings and sign an affidavit stating they have checked their belongings.
 - If syringe found – inventory continues
 - If syringe not found – note made in inventory and count is restarted. PSLS created, Narcotic Incident Report filled out and CC notified of incident.

Documentation:*

- PSLS report entered
- Narcotic Incident Report filled out and left for Clinic Coordinator to review

3.5 Downtime Procedures

If the computers or Profile are not available for any reason, staff will need to remain diligent in their recording of information until the system is once again available. The downtime recording sheet can be found in Appendix A, and staff will need to record:

Pre=Pre Assessment

Post=Post Assessment

P/F=Pass/Fail

CR In= Consumption Room In

CR Out= Consumption Room Out

In order to track how many doses a patient has missed, a record must be kept of any missed doses. In addition to noting the miss on the Missed Dose Table, whenever a patient misses a dose, this should be noted on colored paper and put at the front of the patient's paper chart. Any subsequent *consecutive* missed doses should be recorded on the same sheet, until the patient returns. This sheet can then be disposed of.

It only needs to be recorded when patient's miss consecutive doses.

E.g. If Bob misses his first dose on Wednesday, you note this on the colored paper and enter into the chart. He also misses his second dose on Wednesday, so you add this to the color page. Bob then shows up Thursday morning, so you can dispose of the first page. Again, Bob misses his dose Friday morning, so you begin a new missed dose colored page.

3.6 Missed Dose Protocol

This protocol is for clients that have missed less than 6 doses / sessions.

Missed Dose during titration process:

- If a single dose is missed, the client is provided with the last tolerated dose
- If the patient misses more than one dose then the titration process starts from Day 1

Missed Dose after established on a maintenance dose:

- If 1-6 consecutive doses/sessions are missed, the client will still receive their full regular maintenance dose.

If more than 6 doses/sessions are missed (3 days), then refer to the Missed Days Protocol (3.6).

3.7 Missed Days Protocol

Clinical Indication:

When a client has missed 3 days or 6 consecutive sessions their tolerance for the medication has potentially decreased. This protocol is for > 3 days but ≤ 7 days. For missed sessions <3 days, see the Missed Dose Protocol (3.5).

Policy:

When a client has been absent from the clinic for more than 3 consecutive days but less than or equal to 7 days their injection dose is reduced to 1/2 of the prescribed dose and titrated back up to the prescribed dose as tolerated.

Need to Know:

See appendix B for how to create a dispensing note and pop-up to document dosing information and changes

PRACTICE GUIDELINE

Procedure

- If a patient is absent less than or equal to 3 days, continue with prescribed dose.
- If the patient is absent for more than 3 days and less than or equal to 7 days:
 - Give ½ prescribed dose as per “Missed Days Protocol Table” and increase each dose according to the “Missed Days Protocol Table” until the prescribed (or tolerated) dose is achieved.
- 1. The Absent report is printed off the database every night at the end of the evening shift. It is reviewed by the team daily at morning rounds.
- 2. The harm reduction worker is responsible for contacting the client when they have missed 1 day. This communication is documented in the EMR.
- 3. Clients that have been missing from the clinic for 3 days will have their name entered onto the Pre-waste sheet and the dosing information calculated and filled out on the sheet.
- 4. Pre-waste information is also documented in the database by creating a dispensing note. This dispensing note will create a black alert star by the client name when they are in session
- 5. The dispensing note is read and acknowledged by the assessment nurse who then notifies another nurse of the pre-waste
- 6. The nurse adjusts the dose amount as per the missed day’s protocol, which is verified with the dispensing nurse prior to the clients entering the injection room.
- 7. The correct dosing amount is adjusted into the database when the client’s syringe is scanned for dispensing.
- If a patient is absent over 7 days their prescription will be discontinued by the physician or clinic coordinator and the lost to care algorithm will be implemented.

Missed Days Protocol Table

*For patients who have missed >3 but ≤ 7 days

Dose 1	Provide 50% of the previous maintenance session dose
Dose 2	Provide 75% of the previous maintenance session dose
Dose 3 (next day)	Provide 100% of the previous maintenance dose and continue as per previous maintenance dose.

Patient/Resident Education:

- Clients will be informed of the missed days protocol
- Clients will be informed that if they miss more than one day of treatment at the clinic due to an unplanned absence, someone will contact them in regards to safety.
- Clients will understand that if they miss 3 consecutive days that their dose will be reduced at their first visit back and titrated up during their next visits up to their prescribed dose.

Documentation:*

- Nurses will document dosing information in the database
- Nurses will document dose held/intolerance information and interventions in the EMR
- Nurses will document client contact and attempts to contact client in the EMR.

3.8 Diversion Protocol

Clinical Indication:

To prevent the diversion of Hydromorphone or Diacetylmorphine from the clinic.

Need to Know:

- Clients must be monitored for diversion of medication while they are in the injection room
- Cameras are located in the clinic to monitor the flow of medication through the clinic
- Clients should not be left unattended in the clinic

PRACTICE GUIDELINE

Procedures:

Injection Room Flow to Prevent Diversion:

1. The door to the injection room must be closed at all times
2. Client places belongings in designated area prior to being provided their syringe
3. Client must provide the dispensing nurse with their Name and DOB
4. Client sits or stands at a designated station (injecting in the middle of the room is not allowed).
5. The nurse present in the injection room is responsible for watching the clients inject to prevent diversion attempts.
6. Clients returns all syringe pieces (barrel, needle tip/cap, and label) through the disposal chute.
7. Dispensing Nurse checks that all syringe pieces (barrel, needle tip/cap and label) are accounted for prior to the end of the group time.

If Diversion is witnessed:

- If the client is approachable, quietly address the concern with the client.
- If this is second attempt of diversion for the client, or the client is not approachable, staff must inform the clinic coordinator who will arrange to speak to the client as quickly as possible
- Every attempt should be made to engage client and get diverted medication back

Important Points:

- The door to the injection room must be closed at all times
- There must be only 4 clients in the injection room at a given time
- Client belongings, including coats, must be left in the waiting room
- Each client's injection space should be free from all clutter other than necessary injection supplies
- There must be one staff member in the injection room at all times to respond to emergencies and prevent diversion. Clients may also require assistance with vein care and injection techniques.
- Advise clients to clear their belongings and put them in the appropriate places

- Observing client injection practices
- Keep noise to a minimum
- Watch for hidden receptacles that could be injected into or switched out
- ensuring that at least one staff is monitoring clients if the other is cleaning spaces

Patient/Resident Education:

Clients are made aware at intake that diversion is not tolerated in the clinic

Clients are made aware that if they are caught or suspected of diverting, they will face a one week suspension from the clinic. If a second act of diverting is witnessed, they may face up to 6 months suspension.

Documentation:

If a client is caught or suspected of diversion, the incident must be documented in the EMR. A PSLS report is also required.

3.9 Clinic Contacts and Physician Schedule

The SHOP Clinic adjacent to the iOAT clinic is open from 9am-5pm, Monday through Friday.

If you have a question for an iOAT physician:

- If during SHOP clinic opening hours, **call the clinic** at (604) 583-5666
- If there is no iOAT physician on, or it is outside clinic open hours, **call or text Dr. Henderson** at:
 - Cell – (778) 996-4720

You should always notify the physician if:

- A patient became intoxicated / did not tolerate their dose
- A patient has missed more than 3 days (as an FYI – refer to Missed Days Protocol)

In addition, refer to the Physician On-call list.

Appendix A: iOAT Downtime Recording sheet

iOAT Down Time Recording Sheet

Date:

[illegible]

Appendix B : Client Welcome Statement

Our Vision

We rise to the challenge of the epidemic of addiction by creating opportunities for care, advocacy, and learning.

Our Mission

We:

- Create opportunities for engagement, care, advocacy and learning while recognizing the barriers that exist
- Provide respectful, non-judgemental, diversified care
- Work to promote health of body, mind, and spirit in our clients, ourselves, and our community
- Advocate for a continuing stable treatment program

Clinic Services

1. The Surrey iOAT Clinic is open 7 days a week from 7:00 am to 6:30 pm, including statutory holidays.
2. We close daily between 9:00 – 9:30 am, 12:00 – 1:00 pm, and 4:00 – 4:15 pm for meal breaks.
3. The iOAT clinic works closely with the SHOP clinic, where there are doctors and a Nurse Practitioner on staff.
4. As an iOAT client, you will also have access to the Intensive Case Management team, which can provide other services and supports.
5. Your cooperation and participation is requested when a staff member requests that you complete a Breathalyzer test or provide a urine sample.
6. Discussions regarding dose changes or carries must be addressed with your assigned physician.
7. We will refer you to other health professionals and specialists if needed.
8. We will offer you reminders about appointments and assistance with transportation if needed.

Clinic Rules

1. Everyone is treated with dignity and respect
2. Situations that may result in a behavioral contract, a call to the police, or dismissal from receiving services at the iOAT Clinic include:
 - a. Threatening or violent behavior towards staff or other clients
 - b. Diversion or theft of any medications
 - c. Theft of clinic, staff or client property
 - d. Drug dealing on or around the premises
3. Inappropriate behavior will be dealt with in three steps; a verbal warning, letter of expectation, and a behavior contract. If it continues then we may not be able to continue to provide care for you.
4. You may store your belongings at your own risk at the clinic for a short time while you use the injection room, or when providing a urine sample
5. Staff is not responsible for your belongings, monetary funds, or mail

Rights and Responsibilities of Clients of iOAT Clinic

RIGHTS

1. To feel safe and respected
2. To be unharmed physically, emotionally, and psychologically
3. To be in a clean and supportive environment
4. To receive appropriate support, attention and treatment
5. To have a voice

RESPONSIBILITIES

1. To respect the hours of the clinic and come during posted clinic times
2. To arrive and leave the clinic in an orderly fashion and not loiter
3. To help create and maintain a safe, clean place
4. To not harm others
5. To conduct yourself in a reasonable manner
6. To not use alcohol on-site
7. To not smoke on-site
8. To not deal, exchange, share, or pass anything while in the clinic.
9. To not use or display weapons on-site
10. To care for your own belongings and not leave them at the clinic
11. To not display money
12. To follow direction of Clinic staff
13. To not walk around with an uncapped syringe
14. To not bring pets of any kind into the clinic
15. To not solicit sex on site
16. To respect the property and privacy of others in the clinic

Client's Name (Print)

Client's Signature

Date dd/mmm/yyyy

Name of Witness (Print)

Signature of Witness

Date dd/mmm/yyyy

Appendix C: Hydromorphone Program Agreement and Consent Form

PATIENT INFORMATION

Place Sticker Here

AGREEMENT

I understand and agree that:

- ☐ I am being placed on injectable Hydromorphone (HDM) assisted treatment program.
- ☐ I am aware that the use of Hydromorphone for opiate addiction maintenance is “off label” and is supported with evidence from the NAOMI/SALOME trials.
- ☐ For safety reasons, my physician or nurse practitioner will contact my family physician and any other physicians involved in my care, in order to ensure that each physician is fully aware of the treatment being provided by the other.
- ☐ (If female)I will agree to undergo monthly pregnancy tests.
- ☐ I am aware that my HDM will only be dispensed at the iOAT Clinic.
- ☐ I can attend the clinic up to 2 times per day at designated times.
- ☐ I am aware that there must be a minimum of 3 hours between each dose of HDM.
- ☐ I will provide a urine sample and/or a Breathalyzer test when requested.
- ☐ I will be assessed by the nurse prior to the dispensing of my dose. If I appear drowsy, intoxicated or I am unsteady, the nurse has the right to hold my dose.
- ☐ For any changes in my dose, I will see my physician.
- ☐ If I plan to be away, I will see my physician to discuss my options. I am aware that there are no carry privileges of HDM and a witnessed opioid agonist will be offered.
- ☐ I am expected to attend the clinic consistently and daily. If I am inconsistent in attendance then I will be asked to see my physician and counsellor and other options for treatment of my addictions may be explored.
- ☐ I will not operate a licensed motor driven vehicle whilst receiving HDM.
- ☐ If I miss 3 days in a row, then my dose will be automatically lowered. A staff member will attempt to contact me to discuss my absence. If I miss 7 or more days my HDM prescription will be cancelled and I will need to see my physician to re-titrate or discuss other options.
- ☐ At any time, I may choose another treatment method in place of HDM and my physician/NP and Intensive Case Management team support will facilitate my request.
- ☐ I will be provided full primary care at the SHOP clinic adjacent to iOAT and am not to attend other clinics for primary care (including for routine prescriptions) unless there is an urgent need and when the clinic is closed.

**Pre-Printed Orders for
HYDROMORPHONE iOAT DOSING
TITRATION SCHEDULE**

Client's Name (Print)	Clients Signature	Date dd/mmm/yyyy
Name of Witness (Print)	Signature of Witness	Date dd/mmm/yyyy

Form ID:

Rev:

Page: 1 of 2

DRUG & FOOD ALLERGIES

Appendix D: PPO iOAT 3 Day Titration

- **Mandatory** ☐ **Optional: Prescriber check (✓) to initiate, cross out and initial any orders not indicated.**

- Day 1: HYDROmorphine 15 mg self-administered injection in the morning;
wait 20 minutes and may provide an additional 30 mg dose if tolerated.
HYDROmorphine 45 mg self-administered injection in the afternoon;
wait 20 minutes and may provide an additional 30 mg dose if tolerated.
- Day 2: HYDROmorphine 50 mg self-administered injection in the morning;
wait 20 minutes and may provide an additional 30 mg dose if tolerated.
HYDROmorphine 80 mg self-administered injection in the afternoon;
wait 20 minutes and may provide an additional 20 mg dose if tolerated.
- Day 3 and onward:
HYDROmorphine 70 mg self-administered injection in the morning
HYDROmorphine 100 mg self-administered injection in the afternoon

Missed Dose Titration

- If any doses are missed in the first 3 days of titration, then:
- Provide the last tolerated dose if only one dose is missed
- Restart the titration schedule as "Day 1" if more than one dose is missed

Missed Dose Maintenance

Once on maintenance treatment, if less than 6 consecutive doses are missed, provide the regular maintenance dose

If 6 or more consecutive doses (3 days) are missed, but less than or equal to 7 days, then :

- Provide 50% of the last maintenance dose for Session #1
- Provide 75% of the maintenance dose for Session #2
- Provide 100% of the maintenance dose for Session #3
- Continue at maintenance dose

If more than 7 consecutive days are missed then please refer patient back to the prescriber for further review

Date (dd/mm/yyyy)	Time	Prescriber Signature	Printed Name <u>and</u> College ID#
-------------------	------	----------------------	-------------------------------------

Appendix E: PPO iOAT Individualized Titration

Pre-Printed Orders for HYDROMORPHONE iOAT DOSING (Individualized TITRATION SCHEDULE)

Form ID:

Rev:

Page: 1 of 2

DRUG & FOOD ALLERGIES

- **Mandatory** ☐ **Optional: Prescriber check (✓) to initiate, cross out and initial any orders not indicated.**

- Day 1: HYDROmorphine _____ mg self-administered injection in the morning;
wait 20 minutes and may provide an additional _____ mg dose if tolerated.
HYDROmorphine _____ mg self-administered injection in the afternoon;
wait 20 minutes and may provide an additional _____ mg dose if tolerated.
- Day 2: HYDROmorphine _____ mg self-administered injection in the morning;
wait 20 minutes and may provide an additional _____ mg dose if tolerated.
HYDROmorphine _____ mg self-administered injection in the afternoon;
wait 20 minutes and may provide an additional _____ mg dose if tolerated.
- Day 3: HYDROmorphine _____ mg self-administered injection in the morning;
wait 20 minutes and may provide an additional _____ mg dose if tolerated.
HYDROmorphine _____ mg self-administered injection in the afternoon;
wait 20 minutes and may provide an additional _____ mg dose if tolerated.
- Day 4 and onward:
HYDROmorphine _____ mg self-administered in the morning, and
HYDROmorphine _____ mg self-administered in the afternoon

Missed Dose Titration

- If any doses are missed in the first 3 days of titration, then:
- Provide the last tolerated dose if only one dose is missed
- Restart the titration schedule as "Day 1" if more than one dose is missed

Missed Dose Maintenance

Once on maintenance treatment, if less than 6 consecutive doses are missed, provide the regular maintenance dose

If 6 or more consecutive doses (3 days) are missed, but less than or equal to 7 days, then :

- Provide 50% of the last maintenance dose for Session #1
- Provide 75% of the maintenance dose for Session #2
- Provide 100% of the maintenance dose for Session #3
- Continue at maintenance dose

If more than 7 consecutive days are missed then please refer patient back to the prescriber for further review

Appendix F: PPO iOAT Maintenance

Pre-Printed Orders for HYDROMORPHONE iOAT DOSING MAINTENANCE PRESCRIPTION

Form ID:

Rev:

Page: 1 of 1

DRUG & FOOD ALLERGIES

- **Mandatory** ☐ **Optional: Prescriber check (✓) to initiate, cross out and initial any orders not indicated.**

- HYDROmorphine _____ mg self-administered injection in the morning
- HYDROmorphine _____ mg self-administered injection in the afternoon

If any doses are missed during the maintenance period, then:

- if less than 6 consecutive doses are missed, provide the regular maintenance dose

If 6 or more consecutive doses (3 days) are missed, but less than or equal to 7 days, then :

- Provide 50% of the last maintenance dose for Session #1
- Provide 75% of the maintenance dose for Session #2
- Provide 100% of the maintenance dose for Session #3
- Continue at maintenance dose

If more than 7 consecutive days are missed then please refer patient back to the prescriber for further review

**Pre-Printed Orders for
DIACETYLMORPHINE iOAT DOSING
(TITRATION SCHEDULE)
SHOP Clinic**

Form ID:

Rev:

Page: 1 of 1

DRUG & FOOD ALLERGIES

- **Mandatory** ☐ **Optional: Prescriber check (✓) to initiate, cross out and initial any orders not indicated.**

Date of first session: _____

- ☐ Rapid urine drug testing PRN
- ☐ Breathalyzer PRN
- For ALL doses monitor for signs and symptoms of intoxication for 15 minutes post injection
- Nursing assess for signs and symptoms of opioid sedation and withdrawal before and after each dose using POSS
- Day 1: **diacetylmorphine** 30 mg IV/IM self-administered injection in the morning;
wait 20 minutes and may provide an additional 30 mg dose if tolerated.
diacetylmorphine 60 mg IV/IM self-administered injection in the afternoon;
wait 20 minutes and may provide an additional 30 mg dose if tolerated.
- Day 2: **diacetylmorphine** 90 mg IV/IM self-administered injection in the morning;
wait 20 minutes and may provide an additional 30 mg dose if tolerated.
diacetylmorphine 120 mg IV/IM self-administered injection in the afternoon;
wait 20 minutes and may provide an additional 30 mg dose if tolerated.
- Day 3: **diacetylmorphine** 150 mg IV/IM self-administered injection in the morning;
wait 20 minutes and may provide an additional 30 mg dose if tolerated.
diacetylmorphine 180 mg IV/IM self-administered injection in the afternoon;
wait 20 minutes and may provide an additional 30 mg dose if tolerated.
- Day 4 and ongoing maintenance dose:
diacetylmorphine 180 mg IV/IM self-administered injection in the morning
diacetylmorphine 180 mg IV/IM self-administered injection in the afternoon

Missed Doses on Day 1 to Day 3:

If any iOAT doses are missed in the first 3 days of titration, then:

- If one dose is missed: provide the last tolerated dose and continue with titration
- If more than one dose is missed: restart the titration schedule as Day 1

Missed Maintenance Doses (Day 4 onwards):

- follow Missed Doses Protocol for diacetylmorphine iOAT dosing

From: Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>
 To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>, Alain Boisvert <aboisvert@pharmascience.com>, Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>, kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>, Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>, Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>, Andrea Lee Bailey <albailey@pharmascience.com>, Tupper, Kenneth HLTH:EX
 Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
 Sent: December 7, 2020 3:25:13 PM PST
 Attachments: s.13; s.17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Sorry – a few more Fraser Health documents attached.

Tamar

Cell 604-839-6804
 Administrative Assistant: Jasper Clinaz
jasper.clinaz1@vch.ca

From: Koleba, Tamar [VCH]

Sent: Monday, December 07, 2020 1:31 PM

To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>; 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>

Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>

Subject: RE: s.13; s.17 Pharmascience

Hello,

Please find additional documentation attached from the Fraser Health iOAT Clinic s.13; s.17

Tamar

Cell 604-839-6804
 Administrative Assistant: Jasper Clinaz
jasper.clinaz1@vch.ca

From: Koleba, Tamar [VCH]

Sent: Sunday, December 06, 2020 12:10 PM

To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>; 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>

Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>

Subject: RE: s.13; s.17 Pharmascience

Hi all,

Please find attached some pharmacy and clinic documents from Crosstown Clinic. I will send the Fraser Health Clinic s.13; s.17 and clinic procedures later this week (twice daily administration at the FH clinic).

Thanks,

Tamar

Cell 604-839-6804
 Administrative Assistant: Jasper Clinaz
jasper.clinaz1@vch.ca

From: MacDonald, Scott [PH]
Sent: Friday, December 04, 2020 2:45 PM
To: 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Subject: RE:s.13; s.17 Pharmascience

Hi all,

Thanks for the discussion today. Glad to hear progress is being made toward a s.13; s.17

I have attached some brief answers to the questions. Happy to expand on these s.13

Cheers,

Scott

D. Scott MacDonald M.D.

Physician Lead

Providence Crosstown Clinic

84 West Hastings Street

Vancouver, BC V6B 1G6

Phone: 604-689-8803

Fax: 604-689-3996

Smacdonald2@providencehealth.bc.ca

<https://twitter.com/DrScott>

From: Alain Boisvert [<mailto:aboisvert@pharmascience.com>]
Sent: Wednesday, December 02, 2020 1:09 PM
To: Bouma, Susan HLTH:EX; kenneth.tupper@gov.bc.ca [EXT]; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; MacDonald, Scott [PH]; Eugenia Oviedo-Joekes; Andrea Lee Bailey
Cc: s.22 Bruce Valliant
Subject: RE:s.13; s.17 Pharmascience
EXTERNAL SENDER. If you suspect this message is malicious, please forward to spam@phsa.ca and **do not** open attachments or click on links.

Dear Susan,

In preparation for our meeting of Dec 4, here is a proposed agenda and the questions we would like to raise. It is an broad set of questions but many can be answered rapidly, so hopefully we will be able to cover them all during the meeting.

Once again thank you for making the time, We look forward to meeting you on Friday.

Alain

-----Original Appointment-----

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: Wednesday, November 18, 2020 2:37 PM
To: Bouma, Susan HLTH:EX; Tupper, Kenneth HLTH:EX; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; SMacDonald2@providencehealth.bc.ca; Eugenia Oviedo-Joekes; Alain Boisvert; Andrea Lee Bailey
Cc: s.22 Bruce Valliant
Subject: s.13; s.17 Pharmascience
When: Friday, December 4, 2020 1:00 PM-2:00 PM (UTC-08:00) Pacific Time (US & Canada).
Where: Microsoft Teams Meeting

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

[Learn More](#) | [Meeting options](#)

For instructions on how to download Microsoft Teams click [here](#).

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

Page 128 of 136 to/à Page 133 of 136

Withheld pursuant to/removed as

s.13 ; s.17

From: Andrea Lee Bailey <albailey@pharmascience.com>
To: Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>, MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>, Alain Boisvert <aboisvert@pharmascience.com>, Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>, kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>, Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>, Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>, Tupper, Kenneth HLTH:EX
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Sent: December 8, 2020 6:54:10 AM PST

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Tamar,
Thank you for the documents, and your collaboration.
Regards,
Andrea
Andrea Bailey, PhD.
Senior Regulatory Affairs Specialist – Clinical

Spécialiste principal des affaires règlementaires- Clinique

Pharmascience Inc. | 6111 Royalmount Ave., Montreal (Quebec) H4P 2T4
☎ 1(800) 363-8805 / (438)-315-3494
✉ albailey@pharmascience.com | www.pharmascience.com

From: Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>
Sent: Monday, December 7, 2020 6:25 PM
To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>; Alain Boisvert <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Subject: RE: s.13; s.17 Pharmascience

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Sorry – a few more Fraser Health documents attached.

Tamar

Cell 604-839-6804
Administrative Assistant: Jasper Clinaz
jasper.clinaz1@vch.ca

From: Koleba, Tamar [VCH]
Sent: Monday, December 07, 2020 1:31 PM
To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>; 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Subject: RE: s.13; s.17 Pharmascience

Hello,

Please find additional documentation attached from the Fraser Health iOAT Clinic s.13; s.17

Tamar

Cell 604-839-6804

Administrative Assistant: Jasper Clinaz

jasper.clinaz1@vch.ca

From: Koleba, Tamar [VCH]

Sent: Sunday, December 06, 2020 12:10 PM

To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>; 'Alain Boisvert'

<aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>

Cc:s.22 Bruce Valliant <bvallian@pharmascience.com>

Subject: RE:s.13; s.17 Pharmascience

Hi all,

Please find attached some pharmacy and clinic documents from Crosstown Clinic. I will send the Fraser Health Clinic s.13; s.17 and clinic procedures later this week (twice daily administration at the FH clinic).

Thanks,

Tamar

Cell 604-839-6804

Administrative Assistant: Jasper Clinaz

jasper.clinaz1@vch.ca

From: MacDonald, Scott [PH]

Sent: Friday, December 04, 2020 2:45 PM

To: 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>

Cc:s.22 Bruce Valliant <bvallian@pharmascience.com>

Subject: RE:s.13; s.17 Pharmascience

Hi all,

Thanks for the discussion today. Glad to hear progress is being made toward a s.13; s.17

I have attached some brief answers to the questions. Happy to expand on these s.13

Cheers,

Scott

D. Scott MacDonald M.D.

Physician Lead

Providence Crosstown Clinic

84 West Hastings Street

Vancouver, BC V6B 1G6

Phone: 604-689-8803

Fax: 604-689-3996

Smacdonald2@providencehealth.bc.ca

<https://twitter.com/DrScott>

From: Alain Boisvert [<mailto:aboisvert@pharmascience.com>]

Sent: Wednesday, December 02, 2020 1:09 PM

To: Bouma, Susan HLTH:EX; kenneth.tupper@gov.bc.ca [EXT]; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; MacDonald, Scott [PH]; Eugenia Oviedo-Joekes; Andrea Lee Bailey

Cc:s.22 Bruce Valliant

Subject: RE:s.13; s.17 Pharmascience

EXTERNAL SENDER. If you suspect this message is malicious, please forward to spam@phsa.ca and **do not** open attachments or click on links.

Dear Susan,

In preparation for our meeting of Dec 4, here is a proposed agenda and the questions we would like to raise. It is a broad set of questions but many can be answered rapidly, so hopefully we will be able to cover them all during the meeting.

Once again thank you for making the time, We look forward to meeting you on Friday.

Alain

-----Original Appointment-----

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Sent: Wednesday, November 18, 2020 2:37 PM

To: Bouma, Susan HLTH:EX; Tupper, Kenneth HLTH:EX; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; SMacDonald2@providencehealth.bc.ca; Eugenia Oviedo-Joekes; Alain Boisvert; Andrea Lee Bailey

Cc: s.22 Bruce Valliant

Subject: s.13; s.17 Pharmascience

When: Friday, December 4, 2020 1:00 PM-2:00 PM (UTC-08:00) Pacific Time (US & Canada).

Where: Microsoft Teams Meeting

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

[Learn More](#) | [Meeting options](#)

For instructions on how to download Microsoft Teams click [here](#).

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

FW: Ministry of Health Response - 1167146

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
To: Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>, Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>, Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>
Sent: July 8, 2020 8:36:47 AM PDT
Attachments: image001.jpg
Morning!

Yes and I met with them last Friday. s.13; s.17
s.13; s.17

S

From: Bouma, Susan HLTH:EX
Sent: June 25, 2020 3:25 PM
To: 'Alain Boisvert' <aboisvert@pharmascience.com>; Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>; Scott, Kimberly B HLTH:EX <Kimberly.B.Scott@gov.bc.ca>
Subject: RE: Ministry of Health Response - 1167146

Hi Both:

Tijana is on vacation until the 6th. I am available, however, please connect with Kim for a meeting.

Thanks,
Sue

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: June 25, 2020 12:38 PM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>
Subject: FW: Ministry of Health Response - 1167146

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Susan, Tijana

We have received your response regarding questions raised in our May 25. s.13; s.17
s.13; s.17

s.13; s.17

join me.

Alain

Alain Boisvert, B. Pharm, M.Sc, FOPQ
Head, Government & Public Affairs

Would you have time over the next couple of weeks for a video or tele conference? Kent will

Pharmascience Inc.
6111 avenue Royalmount
Montréal, Québec H4P 2T4
aboisvert@pharmascience.com
(514) 346-4436



From: hlth Pharmaceutical Services Correspondence Unit HLTH:EX <HLTHPSDCORR@gov.bc.ca>
Sent: Friday, June 19, 2020 3:53 PM
To: Alain Boisvert <aboisvert@pharmascience.com>
Subject: Ministry of Health Response - 1167146

1167146

Alain Boisvert
aboisvert@pharmascience.com

Dear Mr. Boisvert:

Thank you for your email of May 25, 2020, s.13; s.17
s.13; s.17

I appreciate the opportunity to respond to these concerns and look forward to working together to resolve this matter.

Sincerely,

Tijana Fazlagic, PharmD, BSP, M.Sc. (Pharm)
Executive Director, PharmaCare Benefits Branch
Pharmaceutical Services Division

WARNING - CONFIDENTIALITY NOTICE: This email is intended only for the use of the individual or organization to which it is addressed. It may contain information that is privileged or confidential. Any distribution, disclosure, copying, or other use by anyone else is strictly prohibited. If you have received this email in error, please telephone or email the sender immediately and delete the message without making any copies.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. **CONFIDENTIALITY NOTICE:**

This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

RE: s.13; s.17

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
To: Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Sent: July 24, 2020 12:24:58 PM PDT
Attachments: image001.jpg

Ok, let's review this when Lynn gets back s.13; s.17

Thanks,
Sue

From: Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>
Sent: July 20, 2020 3:56 PM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Subject: RE: s.13; s.17

Hi Sue,

s.13; s.17

s.13; s.17 I don't believe she has received that info from Mona yet – If I remember correctly, I believe she had said that she was hoping to receive it at some point today.

Let me know if you have any questions.

Thanks,
Mason

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: July 20, 2020 3:40 PM
To: Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>
Cc: Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>
Subject: FW:s.13; s.17

Hi Mason,

Me again. Did you and Lynn happen to come up with s.13; s.17

Thanks,
Sue

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: July 20, 2020 1:28 PM
To: Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>
Subject: s.13; s.17

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Dear Ms. Fazlagic, Ms. Bouma,

Further to our recent communications,^{s.13; s.17}
s.13; s.17

s.13; s.17

Kent and I are at your disposal if you wish to have a direct discussion.

s.13; s.17

Best regards to both of you.

Alain

Alain Boisvert, B. Pharm, M.Sc, FOPQ

Head, Government & Public Affairs

Pharmascience Inc.

6111 avenue Royalmount

Montréal, Québec H4P 2T4

aboisvert@pharmascience.com

(514) 346-4436



From: hlth Pharmaceutical Services Correspondence Unit HLTH:EX <HLTHPSDCORR@gov.bc.ca>

Sent: Friday, June 19, 2020 3:53 PM

To: Alain Boisvert <aboisvert@pharmascience.com>

Subject: Ministry of Health Response - 1167146

1167146

Alain Boisvert
aboisvert@pharmascience.com

Dear Mr. Boisvert:

Thank you for your email of May 25, 2020, s.13; s.17
s.13; s.17

I appreciate the opportunity to respond to these concerns and look forward to working together to resolve this matter.

Sincerely,

Tijana Fazlagic, PharmD, BSP, M.Sc. (Pharm)
Executive Director, PharmaCare Benefits Branch
Pharmaceutical Services Division

WARNING - CONFIDENTIALITY NOTICE: This email is intended only for the use of the individual or organization to which it is addressed. It may contain information that is privileged or confidential. Any distribution, disclosure, copying, or other use by anyone else is strictly prohibited. If you have received this email in error, please telephone or email the sender immediately and delete the message without making any copies.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. **CONFIDENTIALITY NOTICE:** This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

RE: s.13; s.17

From: Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Sent: August 27, 2020 8:57:50 AM PDT
Attachments: image001.jpg

Hi Sue,

s.13; s.17

I can email Tamar about s.13; s.17 but I see you had set up a meeting to discuss tomorrow as well so maybe we should get that from her tomorrow.

Let me know if you would like me to email her or wait until tomorrow 😊

Thanks,
Mason

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: August 27, 2020 8:23 AM
To: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>
Subject: RE: s.13; s.17

Thanks Mason:

s.13; s.17

Sue

From: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Sent: August 26, 2020 4:25 PM
To: Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Subject: RE: s.13; s.17

Thanks, Mason

Our next challenge will be looking at s.13; s.17



L

From: Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>

Sent: August 26, 2020 4:20 PM

To: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Subject: RE: s.13; s.17

Hi Sue and Lynn,

As discussed, I have s.13; s.17

s.13; s.17

Let me know if you have any questions or need anything else for this!

Thanks,

Mason

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Sent: August 24, 2020 9:08 AM

To: Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pugh, Sarah HLTH:EX <Sarah.Pugh@gov.bc.ca>

Cc: Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>

Subject: RE: s.13; s.17

s.13; s.17

S

From: Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>

Sent: August 24, 2020 9:01 AM

To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pugh, Sarah HLTH:EX <Sarah.Pugh@gov.bc.ca>

Cc: Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>

Subject: RE: s.13; s.17

For sure. Does anyone know what they mean by s.13; s.17

Dom

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: August 24, 2020 8:53 AM
To: Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pugh, Sarah HLTH:EX <Sarah.Pugh@gov.bc.ca>
Cc: Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>
Subject: FW: s.13; s.17

Morning!

Can we discuss at business meeting this week please? Hopefully we can have s.13; s.17

Sue

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: August 24, 2020 8:52 AM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>
Subject: s.13; s.17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Susan,

s.13; s.17

s.13; s.17

discussion is needed.

As usual, we are at your disposal if further

Best regards,

Alain
Alain Boisvert, B. Pharm, M.Sc, FOPQ
Head, Government & Public Affairs
Pharmascience Inc.
6111 avenue Royalmount
Montréal, Québec H4P 2T4
aboisvert@pharmascience.com
(514) 346-4436



AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

FW: s.13; s.17

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
To: Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>, Pollock, Lynn L
HLTH:EX <Lynn.Pollock@gov.bc.ca>
Sent: September 2, 2020 8:17:41 AM PDT
Attachments: s.13; s.17 image001.jpg
Here it tis

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: January 9, 2020 6:43 AM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>; Rolando Gonzalez <rgonzale@pharmascience.com>; Monica Montanaro <mmontana@pharmascience.com>; Jean-Guy Goulet <jggoulet@pharmascience.com>
Subject: s.13; s.17

Dear Susan,

All the best for the new year. s.13; s.17
s.13; s.17

I hope you will find this complete and useful. I look forward to our discussion on January 22. Please feel free to call me if you need to discuss any issue beforehand.

Alai

Alain Boisvert, B. Pharm, M.Sc, FOPQ
Head, Government & Public Affairs
Pharmascience Inc.
6111 avenue Royalmount
Montréal, Québec H4P 2T4
aboisvert@pharmascience.com
(514) 346-4436



AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. **CONFIDENTIALITY NOTICE:** This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

Page 12 of 54 to/à Page 17 of 54

Withheld pursuant to/removed as

s.13 ; s.17

RE: s.13; s.17

From: Alain Boisvert <aboisvert@pharmascience.com>
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>, Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>, Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>
Sent: October 1, 2020 11:17:29 AM PDT
Attachments: image001.jpg, image003.jpg

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Sue,

s.13; s.17

s.13; s.17

touch again shortly.

We will be in

Alain

Alain Boisvert, B. Pharm, M.Sc, FOPQ

Head, Government & Public Affairs

Pharmascience Inc.

6111 avenue Royalmount

Montréal, Québec H4P 2T4

aboisvert@pharmascience.com

(514) 346-4436



From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Sent: Thursday, October 1, 2020 1:02 PM

To: Alain Boisvert <aboisvert@pharmascience.com>

Cc: Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>

Subject: s.13; s.17

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Good Morning Alain:

Sorry for the delay in providing you s.13; s.17
s.13; s.17

Let me know if you would like to meet to go through these s.13; s.17

Regards,
Sue (and team)



Susan Bouma (Sue), B.Sc. (Pharm), RPh, PharmD (she/her)

Director, Special Authority Program
Clinical Services and Evaluation Branch
Pharmaceutical, Laboratory & Blood Services Division
Ministry of Health, BC
Ph: 250 952-2506 Fax: 250 952-2216

This email (and any attachment) was intended for a specific recipient.
It may contain information that is privileged, confidential or exempt from disclosure.
Any privilege that exists is not waived. If you are not the intended recipient:
* do not copy it, distribute it to another person or use it for any other purpose; and
* delete it and advise me by return email or telephone.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

From: Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>
To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>, Alain Boisvert <aboisvert@pharmascience.com>, Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>, kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>, Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>, Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>, Andrea Lee Bailey <albailey@pharmascience.com>, Tupper, Kenneth HLTH:EX
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Sent: December 7, 2020 3:25:13 PM PST
Attachments: s.13; s.17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Sorry – a few more Fraser Health documents attached.

Tamar

Cell 604-839-6804
Administrative Assistant: Jasper Clinaz
jasper.clinaz1@vch.ca

From: Koleba, Tamar [VCH]
Sent: Monday, December 07, 2020 1:31 PM
To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>; 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Subject: RE: s.13; s.17 Pharmascience

Hello,

Please find additional documentation attached from the Fraser Health iOAT Clinic s.13; s.17

Tamar

Cell 604-839-6804
Administrative Assistant: Jasper Clinaz
jasper.clinaz1@vch.ca

From: Koleba, Tamar [VCH]
Sent: Sunday, December 06, 2020 12:10 PM
To: MacDonald, Scott [PH] <SMacDonald2@providencehealth.bc.ca>; 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>

Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Subject: RE: s.13; s.17 Pharmascience

Hi all,

Please find attached some pharmacy and clinic documents from Crosstown Clinic. I will send the Fraser Health Clinic s.13; s.17 and clinic procedures later this week (twice daily administration at the FH clinic).

Thanks,

Tamar

Cell 604-839-6804
Administrative Assistant: Jasper Clinaz
jasper.clinaz1@vch.ca

From: MacDonald, Scott [PH]
Sent: Friday, December 04, 2020 2:45 PM
To: 'Alain Boisvert' <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; kenneth.tupper@gov.bc.ca [EXT] <kenneth.tupper@gov.bc.ca>; Koleba, Tamar [VCH] <Tamar.Koleba@vch.ca>; Sutton, Mason HLTH:EX <Mason.Sutton@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Eugenia Oviedo-Joekes <eugenia@cheos.ubc.ca>; Andrea Lee Bailey <albailey@pharmascience.com>
Cc: s.22 Bruce Valliant <bvallian@pharmascience.com>
Subject: RE:s.13; s.17 Pharmascience

Hi all,

Thanks for the discussion today. Glad to hear progress is being made toward a s.13; s.17

I have attached some brief answers to the questions. Happy to expand on these s.13

Cheers,

Scott

D. Scott MacDonald M.D.
Physician Lead
Providence Crosstown Clinic
84 West Hastings Street
Vancouver, BC V6B 1G6
Phone: 604-689-8803
Fax: 604-689-3996
Smacdonald2@providencehealth.bc.ca
<https://twitter.com/DrScott>

From: Alain Boisvert [<mailto:aboisvert@pharmascience.com>]
Sent: Wednesday, December 02, 2020 1:09 PM
To: Bouma, Susan HLTH:EX; kenneth.tupper@gov.bc.ca [EXT]; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; MacDonald, Scott [PH]; Eugenia Oviedo-Joekes; Andrea Lee Bailey
Cc: s.22 Bruce Valliant
Subject: RE: s.13; s.17 Pharmascience

EXTERNAL SENDER. If you suspect this message is malicious, please forward to spam@phsa.ca and **do not** open attachments or click on links.

Dear Susan,

In preparation for our meeting on Dec 4, here is a proposed agenda and the questions we would like to raise. It is a broad set of questions but many can be answered rapidly, so hopefully we will be able to cover them all during the meeting.

Once again thank you for making the time, We look forward to meeting you on Friday.

Alain

-----Original Appointment-----

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Sent: Wednesday, November 18, 2020 2:37 PM

To: Bouma, Susan HLTH:EX; Tupper, Kenneth HLTH:EX; Koleba, Tamar [VCH]; Sutton, Mason HLTH:EX; Pollock, Lynn L HLTH:EX; SMacDonald2@providencehealth.bc.ca; Eugenia Oviedo-Joekes; Alain Boisvert; Andrea Lee Bailey

Cc: s.22 Bruce Valliant

Subject: s.13; s.17 Pharmascience

When: Friday, December 4, 2020 1:00 PM-2:00 PM (UTC-08:00) Pacific Time (US & Canada).

Where: Microsoft Teams Meeting

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

[Learn More](#) | [Meeting options](#)

For instructions on how to download Microsoft Teams click [here](#).

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

Page 23 of 54 to/à Page 28 of 54

Withheld pursuant to/removed as

s.13 ; s.17

RE: 1182077-Response

From: Alain Boisvert <aboisvert@pharmascience.com>
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>, Gauf, Eric HLTH:EX <Eric.Gauf@gov.bc.ca>
Sent: December 17, 2020 2:09:44 PM PST

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Dear Sue,

Thanks for the prompt response. Very helpful.

Alain

-----Original Message-----

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: Thursday, December 17, 2020 5:06 PM
To: Alain Boisvert <aboisvert@pharmascience.com>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Gauf, Eric HLTH:EX <Eric.Gauf@gov.bc.ca>
Subject: Re: 1182077-Response

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Hi Alain:

Good question!

s.13; s.17

Hope that helps!

Dr. Sue Bouma, pharmacist

Special Authority Director
Clinical Services and Evaluation Branch
BC Ministry of Health

Sent from my iPhone

On Dec 17, 2020, at 1:22 PM, Alain Boisvert <aboisvert@pharmascience.com> wrote:

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Dear Sue,

s.13; s.17

Alain
Alain Boisvert, B. Pharm, M.Sc, FOPQ
Head, Government & Public Affairs
Pharmascience Inc.
6111 avenue Royalmount
Montréal, Québec H4P 2T4
aboisvert@pharmascience.com
(514) 346-4436

<image001.jpg>

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: Thursday, December 10, 2020 11:44 AM
To: Alain Boisvert <aboisvert@pharmascience.com>
Subject: RE: 1182077-Response

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.
CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.
Good Morning Alain:

s.13

Sue

From: Alain Boisvert <aboisvert@pharmascience.com<mailto:aboisvert@pharmascience.com>>
Sent: December 10, 2020 6:03 AM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca<mailto:Susan.Bouma@gov.bc.ca>>
Subject: FW: 1182077-Response

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Good morning Sue,

s.13; s.17

Alain

From: El Agab, Charlotte S HLTH:EX <Charlotte.Elagab@gov.bc.ca<mailto:Charlotte.Elagab@gov.bc.ca>> On Behalf Of Moneo, Mitch HLTH:EX

Sent: Tuesday, December 8, 2020 1:42 PM

To: Jean-Guy Goulet <jggoulet@pharmascience.com<mailto:jggoulet@pharmascience.com>>

Cc: Alain Boisvert <aboisvert@pharmascience.com<mailto:aboisvert@pharmascience.com>>

Subject: 1182077-Response

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Dear Mr. Goulet;

Please find the response to your letter of November 20, 2020.

Sincerely,

Mitch Moneo

Assistant Deputy Minister

Pharmaceutical, Laboratory and Blood Services Division, Ministry of Health

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

RE: s.13; s.17

From: Pollock, Lynn L HLTH:EX
s.15
To: Kimberly B HLTH:EX Scott (Kimberly.B.Scott@gov.bc.ca)
Sent: February 11, 2021 12:03:11 PM PST
Attachments: image001.jpg

Yes if I can be on it would be great

From: Kent Major <kmajor@pharmascience.com>
Sent: February 11, 2021 12:02 PM
To: Scott, Kimberly B HLTH:EX <Kimberly.B.Scott@gov.bc.ca>; Alain Boisvert <aboisvert@pharmascience.com>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Subject: RE:s.13;
e 17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Sure.

Kent R.J. Major
Vice President, Global Regulatory Affairs, Drug Safety and Risk Management
Pharmascience Inc.
6111 Royalmount Ave
Montreal, Quebec
H4P 2T4

kmajor@pharmascience.com
mobile: +5145668812
office: +5143405060

From: Scott, Kimberly B HLTH:EX <Kimberly.B.Scott@gov.bc.ca>
Sent: Thursday, February 11, 2021 3:01 PM
To: Alain Boisvert <aboisvert@pharmascience.com>; Kent Major <kmajor@pharmascience.com>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Subject: RE:s.13;
e 17

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Hello,

Would you be available for a quick call right now? Sue has no other availability otherwise.

Thanks,

Kimberly B. Scott | Administrative Assistant
Special Authority | Clinical Services And Evaluation Branch
Pharmaceutical, Laboratory and Blood Services Division
Ministry of Health
Kimberly.B.Scott@gov.bc.ca
236 478-1313

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: February 11, 2021 11:55 AM
To: Kent Major <kmajor@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Scott, Kimberly B HLTH:EX <Kimberly.B.Scott@gov.bc.ca>
Subject: RE:s.13;
s.17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Same for me. I will make myself available if today works for you.

Alain

From: Kent Major <kmajor@pharmascience.com>
Sent: Thursday, February 11, 2021 2:54 PM
To: Alain Boisvert <aboisvert@pharmascience.com>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Scott, Kimberly B HLTH:EX <Kimberly.B.Scott@gov.bc.ca>
Subject: RE:s.13; s.17

I can be available this afternoon up until 5 pm EST (2 pm Pacific).
Please let me know if this is possible.

Kent R.J. Major
Vice President, Global Regulatory Affairs, Drug Safety and Risk Management
Pharmascience Inc.
6111 Royalmount Ave
Montreal, Quebec
H4P 2T4

kmajor@pharmascience.com
mobile: +5145668812
office: +5143405060

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: Thursday, February 11, 2021 2:47 PM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Kent Major <kmajor@pharmascience.com>; Scott, Kimberly B HLTH:EX <Kimberly.B.Scott@gov.bc.ca>
Subject: RE: s.13;
s.17

I am taking the day off tomorrow, would you have time later this afternoon, subject to Kent' availability?

Alain

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: Thursday, February 11, 2021 2:44 PM
To: Alain Boisvert <aboisvert@pharmascience.com>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Kent Major <kmajor@pharmascience.com>; Scott, Kimberly B HLTH:EX <Kimberly.B.Scott@gov.bc.ca>
Subject: RE: s.13;
s.17

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.
CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

We have a meeting with HC tomorrow at 9 am. Can we try for 8:30? Just before?

S

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: February 11, 2021 9:50 AM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Kent Major <kmajor@pharmascience.com>
Subject: RE:s.13;

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Yes, at your convenience. I will involve Kent, who oversees the file with Health Canada.

Alain

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: Thursday, February 11, 2021 11:32 AM
To: Alain Boisvert <aboisvert@pharmascience.com>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Subject: RE: s.13;
s.17

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Hi Alain:

Do you have any time to have a quick chat?

Best,
Sue

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: January 14, 2021 2:41 PM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Subject: RE: s.13;
s.17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Sue,

s.13; s.17

Alain

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: Thursday, January 14, 2021 5:34 PM
To: Alain Boisvert <aboisvert@pharmascience.com>

Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>

Subject: s.13;
s.17

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Hi Alain:

s.13; s.17

Best,
Sue



Susan Bouma (Sue), B.Sc. (Pharm), RPh, PharmD (she/her)

Director, Special Authority Program
Clinical Services and Evaluation Branch
Pharmaceutical, Laboratory & Blood Services Division
Ministry of Health, BC
Ph: 250 952-2506 Fax: 250 952-2216

This email (and any attachment) was intended for a specific recipient.
It may contain information that is privileged, confidential or exempt from disclosure.
Any privilege that exists is not waived. If you are not the intended recipient:
* do not copy it, distribute it to another person or use it for any other purpose; and
* delete it and advise me by return email or telephone.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

RE: s.13; s.17

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
To: Kent Major <kmajor@pharmascience.com>, Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>, Maglanque, Joyce HLTH:EX <Joyce.Maglanque@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Cc: Alain Boisvert <aboisvert@pharmascience.com>, Deirdre Cozier <dcozier@pharmascience.com>, Saranette Cheng <scheng@pharmascience.com>
Sent: April 28, 2021 3:57:07 PM PDT
Hello Kent!

s.13; s.17

Sue

From: Kent Major <kmajor@pharmascience.com>
Sent: April 28, 2021 6:39 AM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Alain Boisvert <aboisvert@pharmascience.com>; Deirdre Cozier <dcozier@pharmascience.com>; Saranette Cheng <scheng@pharmascience.com>
Subject: s.13; s.17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Good morning Sue,
s.13; s.17

Best regards,

Kent R.J. Major
Vice President, Global Regulatory Affairs, Drug Safety and Risk Management
Pharmascience Inc.
6111 Royalmount Ave
Montreal, Quebec
H4P 2T4

kmajor@pharmascience.com
mobile: +5145668812
office: +5143405060

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

RE: NOT URGENT - Couple of thoughts

From: Alain Boisvert <aboisvert@pharmascience.com>
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>, Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>, Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>, Bruce Valliant <bvallian@pharmascience.com>, Andrea Lee Bailey <albailey@pharmascience.com>, Naumann, Terryn HLTH:EX <Terryn.Naumann@gov.bc.ca>
Sent: May 7, 2021 12:15:36 PM PDT

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Sue,

Yes we will arrange the meeting with Lynn and Dom. I will get back to you with tentative dates.

Look forward to talking to you upon your return.

Alain

-----Original Message-----

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: Thursday, May 6, 2021 11:34 PM
To: Alain Boisvert <aboisvert@pharmascience.com>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>; Bruce Valliant <bvallian@pharmascience.com>; Andrea Lee Bailey <albailey@pharmascience.com>; Naumann, Terryn HLTH:EX <Terryn.Naumann@gov.bc.ca>
Subject: Re: NOT URGENT - Couple of thoughts

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

s.13; s.17

Sorry!

Dr. Sue Bouma, pharmacist

Special Authority Director
Clinical Services and Evaluation Branch
BC Ministry of Health

Sent from my iPhone

On May 6, 2021, at 11:25 AM, Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca> wrote:

Ok! Excellent. Thanks Alain.

Best,
Sue

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: May 4, 2021 11:52 AM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>; Bruce Valliant <bvallian@pharmascience.com>; Andrea Lee Bailey <albailey@pharmascience.com>
Subject: RE: NOT URGENT - Couple of thoughts

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Sue,

s.13; s.17

Alain

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca<mailto: Susan.Bouma@gov.bc.ca>>
Sent: Tuesday, May 4, 2021 1:01 PM
To: Alain Boisvert <aboisvert@pharmascience.com<mailto: aboisvert@pharmascience.com>>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca<mailto: Dominic.Tan@gov.bc.ca>>
Cc: Kent Major <kmajor@pharmascience.com<mailto: kmajor@pharmascience.com>>; Bruce Valliant <bvallian@pharmascience.com<mailto: bvallian@pharmascience.com>>; Andrea Lee Bailey <albailey@pharmascience.com<mailto: albailey@pharmascience.com>>
Subject: RE: NOT URGENT - Couple of thoughts

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.
CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless

you recognize the sender and know the content is safe.

Good Morning!

s.13; s.17

Best,

Sue

From: Alain Boisvert <aboisvert@pharmascience.com<mailto:aboisvert@pharmascience.com>>

Sent: April 30, 2021 11:23 AM

To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca<mailto:Susan.Bouma@gov.bc.ca>>

Cc: Kent Major <kmajor@pharmascience.com<mailto:kmajor@pharmascience.com>>; Bruce Valliant <bvallian@pharmascience.com<mailto:bvallian@pharmascience.com>>; Andrea Lee Bailey <albailey@pharmascience.com<mailto:albailey@pharmascience.com>>

Subject: NOT URGENT - Couple of thoughts

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Sue,

I would like to share a couple of thoughts. s.13; s.17

s.13; s.17

TBD. Have a good week end,

Alain

Alain Boisvert, B. Pharm, M.Sc, FOPQ

Head, Government & Public Affairs

Pharmascience Inc.

6111 avenue Royalmount

Montréal, Québec H4P 2T4

aboisvert@pharmascience.com<mailto:aboisvert@pharmascience.com>

(514) 346-4436

<image001.jpg>

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

RE: s.13; s.17

From: Pollock, Lynn L HLTH:EX
s.15
To: Alain Boisvert, Tan, Dominic HLTH:EX, Naumann, Terryn HLTH:EX, Bouma, Susan HLTH:EX
Cc: Kent Major, Bruce Valliant, Andrea Lee Bailey, Sarah Douglas, Fazlagic, Tijana HLTH:EX, Koleba, Tamar [VCH]
Sent: May 11, 2021 8:41:52 AM PDT
Attachments: image001.jpg

Great. Thank you, Alain. I'll confirm the day asap.

Lynn

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: May 11, 2021 8:40 AM
To: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>; Naumann, Terryn HLTH:EX <Terryn.Naumann@gov.bc.ca>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>; Bruce Valliant <bvallian@pharmascience.com>; Andrea Lee Bailey <albailey@pharmascience.com>; Sarah Douglas <sdouglas@pharmascience.com>; Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>
Subject: RE: s.13; s.17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Lynn,

Here are the topics we would need to discuss.

s.13; s.17

Let me know if it makes sense, or if you want to add other topics.

Alain

Alain Boisvert, B. Pharm, M.Sc, FOPQ

Head, Government & Public Affairs

Pharmascience Inc.

6111 avenue Royalmount

Montréal, Québec H4P 2T4

aboisvert@pharmascience.com

(514) 346-4436



Together, let's support local businesses!
Choosing Pharmascience is choosing local, and contributing to the Canadian economy. Pharmascience employs nearly 1,500 people across the country.

From: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>

Sent: Tuesday, May 11, 2021 11:02 AM

To: Alain Boisvert <aboisvert@pharmascience.com>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>; Naumann, Terry HLTH:EX <Terry.Naumann@gov.bc.ca>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Cc: Kent Major <kmajor@pharmascience.com>; Bruce Valliant <bvallian@pharmascience.com>; Andrea Lee Bailey <albailey@pharmascience.com>; Sarah Douglas <sdouglas@pharmascience.com>; Fazlagic, Tijana HLTH:EX <Tijana.Fazlagic@gov.bc.ca>

Subject: RE:s.13; s.17

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Hi Alain

I will check today to make that the day/times still work for everyone and aim the 18 or 19. Would you please outline for me what we specifically need to discuss so that I can make sure that the right people are in attendance from the Ministry side.

Thank you
Lynn

From: Alain Boisvert <aboisvert@pharmascience.com>

Sent: May 11, 2021 6:09 AM

To: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>; Naumann, Terry HLTH:EX <Terry.Naumann@gov.bc.ca>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Cc: Kent Major <kmajor@pharmascience.com>; Bruce Valliant <bvallian@pharmascience.com>; Andrea Lee Bailey <albailey@pharmascience.com>; Sarah Douglas <sdouglas@pharmascience.com>

Subject: RE:s.13; s.17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Good morning Lynn,

Best dates for the PMS team would be May 18 or 19 at 12 PST/15 EST. We can also make it on May 25 but would prefer an earlier meeting s.13; s.17

s.13; s.17

Unfortunately May 21 does not work. Let me know your preference. Also, is it possible to do it on Teams or Zoom? We are experiencing problems with Skype, so I would feel safer on the former two channels.

Alain

From: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>

Sent: Monday, May 10, 2021 4:25 PM

To: Alain Boisvert <aboisvert@pharmascience.com>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>; Naumann, Terry HLTH:EX <Terry.Naumann@gov.bc.ca>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Cc: Kent Major <kmajor@pharmascience.com>; Bruce Valliant <bvallian@pharmascience.com>; Andrea Lee Bailey <albailey@pharmascience.com>; Sarah Douglas <sdouglas@pharmascience.com>

Subject: RE: s.13; s.17

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Hi Alain

Yes, for sure we would be happy to meet with you. Here are some dates that at the moment seem to work for Dom, Terryn and myself

Tues May 18: 12-1pm (PST)

Wed May 19: 12-1pm (PST)

Fri May 21: 11-11:30am OR 1-1:30pm (PST)

Tues May 25: 2-3pm (PST)

I think the Fri 21 or Tues 25 dates might be preferred from this end but can meet at any of those times if they fit your schedule.

Hope one of these times works.

Lynn

Lynn Pollock B.Sc.(Pharm.), RPh (she/her)
Clinical Pharmacist, Drug Safety
MoH Liaison BC PMP
Therapeutic Assessment and Access Branch
Pharmaceutical, Laboratory and Blood Services Division
BC Ministry of Health
1515 Blanshard Street
Victoria, BC
V8W 3C8

Tel: 250-952-2884 cell: 250-812-9107

I respectfully acknowledge with gratitude that I live, work and play on the unceded traditional territory of the Lekwungen peoples - Songhees, Esquimalt, and WSANEC Nations

From: Alain Boisvert <aboisvert@pharmascience.com>

Sent: May 10, 2021 1:11 PM

To: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>; Naumann, Terryn HLTH:EX <Terryn.Naumann@gov.bc.ca>; Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Cc: Kent Major <kmajor@pharmascience.com>; Bruce Valliant <bvallian@pharmascience.com>; Andrea Lee Bailey <albailey@pharmascience.com>; Sarah Douglas <sdouglas@pharmascience.com>

Subject: s.13; s.17

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Lynn,

I am following up, subsequent to the exchange with Sue below, to set up a first meeting where we can discuss these matters. s.13; s.17

s.13; s.17

s.13; s.17

s.13; s.17

If you could share a few dates over the next two weeks, that would be great. The people copied on this email will constitute the PMS team.

s.13; s.17

We can agree on a preliminary agenda once we have a date set in calendar.

Best regards,

Alain

Alain Boisvert, B. Pharm, M.Sc, FOPQ

Head, Government & Public Affairs


Pharmascience Inc.

6111 avenue Royalmount

Montréal, Québec H4P 2T4

aboisvert@pharmascience.com

(514) 346-4436



From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>

Sent: Thursday, May 6, 2021 2:26 PM

To: Alain Boisvert <aboisvert@pharmascience.com>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>; Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>

Cc: Kent Major <kmajor@pharmascience.com>; Bruce Valliant <bvallian@pharmascience.com>; Andrea Lee Bailey <albailey@pharmascience.com>; Naumann, Terryn HLTH:EX <Terryn.Naumann@gov.bc.ca>

Subject: RE: NOT URGENT - Couple of thoughts

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Ok! Excellent. Thanks Alain.

s.13; s.17

Best,
Sue

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: May 4, 2021 11:52 AM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>; Bruce Valliant <bvallian@pharmascience.com>; Andrea Lee Bailey <albailey@pharmascience.com>
Subject: RE: NOT URGENT - Couple of thoughts

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Sue,

s.13; s.17

Alain

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: Tuesday, May 4, 2021 1:01 PM
To: Alain Boisvert <aboisvert@pharmascience.com>; Tan, Dominic HLTH:EX <Dominic.Tan@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>; Bruce Valliant <bvallian@pharmascience.com>; Andrea Lee Bailey <albailey@pharmascience.com>
Subject: RE: NOT URGENT - Couple of thoughts

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.

CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Good Morning!

s.13; s.17

Best,
Sue

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: April 30, 2021 11:23 AM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Kent Major <kmajor@pharmascience.com>; Bruce Valliant <bvallian@pharmascience.com>; Andrea Lee Bailey

<albailey@pharmascience.com>

Subject: NOT URGENT - Couple of thoughts

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Sue,

I would like to share a couple of thoughts. s.13; s.17
s.13; s.17

TBD. Have a good week end,

Alain

Alain Boisvert, B. Pharm, M.Sc, FOPQ

Head, Government & Public Affairs

Pharmascience Inc.

6111 avenue Royalmount

Montréal, Québec H4P 2T4

aboisvert@pharmascience.com

(514) 346-4436



Together, let's support local businesses!

Choosing Pharmascience is choosing local, and contributing to the Canadian economy. Pharmascience employs nearly 1,500 people across the country.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. **CONFIDENTIALITY NOTICE:** This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. **CONFIDENTIALITY NOTICE:** This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. **CONFIDENTIALITY NOTICE:**

This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

.msg

From: Pollock, Lynn L HLTH:EX s.15
To: Kent Major, Bruce Valliant, Alain Boisvert, Sarah Douglas, Tijana HLTH:EX Fazlagic (Tijana.Fazlagic@gov.bc.ca), Naumann, Terryn HLTH:EX, Tan, Dominic HLTH:EX, Andrea Lee Bailey
Sent: May 11, 2021 11:23:30 AM PDT
Priority: Normal (5)
Calendar Item Type: REQUEST

Accepted s.13; s.17

.msg

From: Lisa Fianza <lfianza@pharmascience.com>
To: Pollock, Lynn L HLTH:EX
Sent: May 11, 2021 5:27:39 PM PDT

Priority: Normal (5)
Calendar Item Type: REPLY

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

Automatic reply: s.13; s.17

From: Kent Major <kmajor@pharmascience.com>
To: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Sent: May 18, 2021 11:59:11 AM PDT

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Thank you for your email; I will be out of the office with limited access to my emails.

For all urgent matters; please contact me at +1-514-566-8812.

Thank you,
Kent

Merci pour votre courriel; Je serai absent du bureau avec un accès limité à mes courriels.

Pour toutes urgences, s'il vous plaît veuillez me contacter sur mon cellulaire au +1-514-566-8812.

Merci,
Kent

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. **CONFIDENTIALITY NOTICE:** This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

Question re: s.13; s.17

From: Andrea Lee Bailey <albailey@pharmascience.com>
To: SMacDonald2@providencehealth.bc.ca
Cc: Lynn.Pollock@gov.bc.ca, Bruce Valliant <bvallian@pharmascience.com>, Pollock, Lynn L HLTH:EX
Sent: May 19, 2021 11:33:12 AM PDT
Attachments: image001.gif

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Good afternoon,

s.13; s.17

Kind regards,

Andrea

Andrea Bailey, PhD.

Senior Regulatory Affairs Specialist – Clinical
Spécialiste principal des affaires règlementaires- Clinique

Pharmascience Inc. | 6111 Royalmount Ave., Montreal (Quebec) H4P 2T4

☎ 1(800) 363-8805 / (438)-315-3494

✉ albailey@pharmascience.com | www.pharmascience.com

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. **CONFIDENTIALITY NOTICE:** This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.

From: [Bouma, Susan HLTH:EX](#)
To: "Alain Boisvert"
Cc: [Pollock, Lynn L HLTH:EX](#)
Subject: RE:s.13;
Date: January 14, 2021 4:08:56 PM

Thanks Alain!

From: Alain Boisvert <aboisvert@pharmascience.com>
Sent: January 14, 2021 2:41 PM
To: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Subject: RE: DAM

[EXTERNAL] This email came from an external source. Only open attachments or links that you are expecting from a known sender.

Hi Sue,

s.13; s.17

Alain

From: Bouma, Susan HLTH:EX <Susan.Bouma@gov.bc.ca>
Sent: Thursday, January 14, 2021 5:34 PM
To: Alain Boisvert <aboisvert@pharmascience.com>
Cc: Pollock, Lynn L HLTH:EX <Lynn.Pollock@gov.bc.ca>
Subject:s.13;
s.17

ATTENTION: Ce courriel provient de l'extérieur de l'organisation. Ne cliquez pas sur des liens ou n'ouvrez pas des pièces jointes à moins de reconnaître l'expéditeur et de savoir que le contenu est sécuritaire.
CAUTION: This email originates from outside of the organization. Do not click on the links or open attachments unless you recognize the sender and know the content is safe.

Hi Alain:

s.13; s.17

Best,
Sue



Susan Bouma (Sue), B.Sc. (Pharm), RPh, PharmD (she/her)

Director, Special Authority Program
Clinical Services and Evaluation Branch
Pharmaceutical, Laboratory & Blood Services Division
Ministry of Health, BC
Ph: 250 952-2506 Fax: 250 952-2216

This email (and any attachment) was intended for a specific recipient.
It may contain information that is privileged, confidential or exempt from disclosure.
Any privilege that exists is not waived. If you are not the intended recipient:
* do not copy it, distribute it to another person or use it for any other purpose; and
* delete it and advise me by return email or telephone.

AVIS DE CONFIDENTIALITÉ : Ce message peut contenir de l'information légalement privilégiée ou confidentielle. Si vous n'êtes pas le destinataire ou croyez avoir reçu par erreur ce message, nous vous saurions gré d'en aviser l'émetteur et d'en détruire le contenu sans le communiquer à d'autres ou le reproduire. CONFIDENTIALITY NOTICE: This communication may contain privileged or confidential information. If you are not the intended recipient or received this communication by error, please notify the sender and delete the message without copying or disclosing it.